Literature DB >> 16109314

Serum interleukin-15 concentration in patients with essential hypertension.

Masaharu Kaibe1, Mitsuru Ohishi, Norihisa Ito, Ming Yuan, Takashi Takagi, Minako Terai, Yuji Tatara, Norio Komai, Hiromi Rakugi, Toshio Ogihara.   

Abstract

BACKGROUND: Interleukin (IL)-15 is one of the cytokines produced by neutrophils and monocytes/macrophages, and its expression is found immunohistochemically in inflammatory cells adjacent to vulnerable atherosclerotic plaques. However, the influence of systemic IL-15 on cardiovascular disease is still unclear. Therefore, we designed clinical investigations to clarify the relationship between cardiovascular complications and serum IL-15 levels. METHODS AND
RESULTS: Three hundred ninety-nine patients with essential hypertension were analyzed. We divided the study subjects into the following three groups according to the modified World Health Organization-International Society of Hypertension classification of 1999: patients with no organ damage (n = 213), patients with mild organ damage (n = 128), and patients with severe organ damage (n = 58). We measured serum IL-15, highly sensitive C reactive protein, IL-6, soluble intercellular adhesion molecule, and soluble vascular cell adhesion molecule levels. Serum IL-15 concentration in patients with severe organ damage was significantly higher than that in those with no organ damage (P < .01) and those with mild organ damage (P < .01). Serum IL-15 concentration in patients with coronary artery disease or peripheral artery disease was significantly higher than that in those without coronary artery disease or peripheral artery disease. Moreover, serum IL-15 concentration in patients with lacunar infarction was significantly higher than that in those without lacunar infarction (P < .005). By multiple linear logistic regression analysis, serum IL-15 concentration was independently correlated with cardiovascular disease.
CONCLUSIONS: These data suggest that a systemic inflammatory response involving IL-15 might be involved in the occurrence of cardiovascular disease in patients with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16109314     DOI: 10.1016/j.amjhyper.2005.02.014

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  13 in total

1.  Novel genetic variants contributing to left ventricular hypertrophy: the HyperGEN study.

Authors:  Donna K Arnett; Richard B Devereux; Dabeeru C Rao; Na Li; Weihong Tang; Rachel Kraemer; Steven A Claas; Joanlise M Leon; Ulrich Broeckel
Journal:  J Hypertens       Date:  2009-08       Impact factor: 4.844

2.  Expanded network of inflammatory markers of atherogenesis: where are we now?

Authors:  Seyed Hesameddin Abbasi; Mohammad Ali Boroumand
Journal:  Open Cardiovasc Med J       Date:  2010-02-23

Review 3.  Activated T-effector seeds: cultivating atherosclerotic plaque through alternative activation.

Authors:  Maria M Xu; Patrick A Murphy; Anthony T Vella
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-03-29       Impact factor: 5.125

4.  Interleukin-15 and soluble interleukin-15 receptor α in coronary artery disease patients: association with epicardial fat and indices of adipose tissue distribution.

Authors:  Elena Dozio; Alexis Elias Malavazos; Elena Vianello; Silvia Briganti; Giada Dogliotti; Francesco Bandera; Francesca Giacomazzi; Serenella Castelvecchio; Lorenzo Menicanti; Alexander Sigrüener; Gerd Schmitz; Massimiliano Marco Corsi Romanelli
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

Review 5.  Role of interleukin-15 in cardiovascular diseases.

Authors:  Lei Guo; Ming-Fei Liu; Ji-Niu Huang; Jia-Min Li; Jun Jiang; Jian-An Wang
Journal:  J Cell Mol Med       Date:  2020-05-14       Impact factor: 5.310

Review 6.  Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker?

Authors:  Daniela Maria Tanase; Evelina Maria Gosav; Smaranda Radu; Anca Ouatu; Ciprian Rezus; Manuela Ciocoiu; Claudia Florida Costea; Mariana Floria
Journal:  Int J Hypertens       Date:  2019-05-02       Impact factor: 2.420

7.  Search for New Candidate Genes Involved in the Comorbidity of Asthma and Hypertension Based on Automatic Analysis of Scientific Literature.

Authors:  Olga V Saik; Pavel S Demenkov; Timofey V Ivanisenko; Elena Yu Bragina; Maxim B Freidin; Victor E Dosenko; Olga I Zolotareva; Evgeniy L Choynzonov; Ralf Hofestaedt; Vladimir A Ivanisenko
Journal:  J Integr Bioinform       Date:  2018-12-25

8.  Age and Interleukin-15 Levels Are Independently Associated With Intima-Media Thickness in Obesity-Related NAFLD Patients.

Authors:  Giovanni Tarantino; Vincenzo Citro; Clara Balsano; Domenico Capone
Journal:  Front Med (Lausanne)       Date:  2021-05-21

9.  Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease.

Authors:  Dirk M Wuttge; Marie Wildt; Pierre Geborek; Frank A Wollheim; Agneta Scheja; Anita Akesson
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

10.  Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension.

Authors:  Rajeev Malhotra; Samuel Paskin-Flerlage; Roham T Zamanian; Patrick Zimmerman; Jonathan W Schmidt; Donna Y Deng; Mark Southwood; Robert Spencer; Carol S Lai; William Parker; Richard N Channick; Nicholas W Morrell; C Gregory Elliott; Paul B Yu
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.